Prelude Capital Management’s State Street SPDR S&P Biotech ETF XBI Stock Holding History

Prelude Capital Management’s Portfolio XBI Stock Details XBI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$791K	Buy	+5,000	New	+$676K	0.06%	377
2025 Q3	–	Sell	-15,000	Closed	-$1.24M	–	1418
2025 Q2	$1.24M	Buy	15,000 +986	+7%	+$78.7K	0.12%	211
2025 Q1	$1.14M	Buy	+14,014	New	+$1.25M	0.09%	279
2024 Q4	–	Sell	-4,130	Closed	-$408K	–	1597
2024 Q3	$408K	Buy	+4,130	New	+$406K	0.02%	711
2024 Q1	–	Sell	-3,440	Closed	-$307K	–	1554
2023 Q4	$307K	Buy	3,440 +294	+9%	+$21.8K	0.02%	726
2023 Q3	$230K	Buy	+3,146	New	+$251K	0.02%	824
2021 Q3	–	Sell	-9,797	Closed	-$1.33M	–	2060
2021 Q2	$1.33M	Buy	+9,797	New	+$1.29M	0.04%	465
2015 Q2	–	Sell	-6,300	Closed	-$474K	–	2083
2015 Q1	$474K	Buy	+6,300	New	+$440K	0.07%	358

Other funds holding XBI

BNP Paribas Financial Markets Paris, France $289B AUM 60.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Citigroup New York $303B AUM 53.02% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $71.2B AUM 48.86% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return

JFG

Jefferies Financial Group New York $15.2B AUM 55.75% 1-Year Est. Return

Prelude Capital Management's XBI Position: Q2 2026 in Review

Prelude Capital Management opened a new position in State Street SPDR S&P Biotech ETF (XBI) in Q2 2026: 5,000 shares worth $791K. The stake represents 0.06% of the portfolio and ranks #377 among its holdings. This is a return to the name: Prelude Capital Management previously reported a position in XBI as recently as Q2 2025.

Prelude Capital Management first reported a position in XBI in Q1 2015 and has held it in 8 quarters since. The position peaked at $1.33M in Q2 2021. 934 funds tracked by Wall St. Rank hold XBI as of Q2 2026.

Prelude Capital Management held 5,000 shares of State Street SPDR S&P Biotech ETF worth $791K as of Q2 2026.
State Street SPDR S&P Biotech ETF was a new Prelude Capital Management position in Q2 2026.
State Street SPDR S&P Biotech ETF made up 0.06% of Prelude Capital Management's portfolio in Q2 2026, its #377 holding.
Prelude Capital Management first reported a position in State Street SPDR S&P Biotech ETF in Q1 2015 and has held it in 8 quarters since.
Prelude Capital Management's State Street SPDR S&P Biotech ETF position peaked at $1.33M in Q2 2021.
934 funds tracked by Wall St. Rank held State Street SPDR S&P Biotech ETF as of Q2 2026.

Based on Prelude Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.